Management and Prevention of Bone Complications Supportive Care


Xgeva Reduces Bone Complications From Prostate Cancer (February 25, 2011)

Among men with bone metastases from prostate cancer, Xgeva™ (denosumab) was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from... Continue Reading

Xgeva Delays Bone Complications in Women with Metastatic Breast Cancer (December 21, 2010)

In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III... Continue Reading

Xgeva Approved for Patients with Bone Metastases (November 30, 2010)

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related)... Continue Reading

Denosumab Delays Bone Complications in Women with Metastatic Breast Cancer (November 23, 2010)

Among women with bone metastases from breast cancer, denosumab may be more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase... Continue Reading

Denosumab More Effective Than Zometa at Delaying Bone Complications (October 15, 2010)

Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing... Continue Reading

Denosumab More Effective Than Zometa in Prostate Cancer Patients with Bone Metastases (February 10, 2010)

Among men with bone metastases from prostate cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture.... Continue Reading

Bisphosphonates May Provide Breast Cancer Benefits (December 10, 2009)

Studies presented at the 2009 San Antonio Breast Cancer Symposium suggest that the class of bone drugs known as bisphosphonates may reduce the risk of breast cancer and may help to maintain bone density... Continue Reading

Denosumab Reduces Bone Complications in Breast Cancer Patients with Bone Metastases (December 10, 2009)

Among women with bone metastases from breast cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture.... Continue Reading

Denosumab More Effective Than Zometa in Breast Cancer Patients with Bone Metastases (September 22, 2009)

Among women with bone metastases from breast cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase... Continue Reading

Denosumab Provides Bone Benefits in Advanced Cancer (September 21, 2009)

Among patients with bone metastases from cancers other than breast or prostate cancer, denosumab is at least as effective as Zometa® (zoledronic acid) at reducing the risk of bone complications. These... Continue Reading

Denosumab Reduces Fractures in Postmenopausal Osteoporosis (August 12, 2009)

Denosumab increases bone mineral density (BMD) and reduces the risk of vertebral fractures in women with postmenopausal osteoporosis, according to the results of a study published in the New England Journal... Continue Reading

Denosumab Reduces Fractures in Non-metastatic Prostate Cancer (August 11, 2009)

Men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer experienced a 62% reduction in risk of vertebral fractures when treated with denosumab compared to men treated with... Continue Reading

Denosumab Effective in Patients with Bone Metastases (August 7, 2009)

Among patients with bone metastases from cancers other than breast cancer or prostate cancer, the investigational drug denosumab was as effective as Zometa® (zoledronic acid) at reducing the risk of bone... Continue Reading

Denosumab More Effective than Zometa® in Patients with Bone Metastases (July 8, 2009)

Among women with bone metastases from breast cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at reducing the risk of bone complications such as fracture. The... Continue Reading

Denosumab Reduces the Risk of Bone Fractures (September 17, 2008)

Denosumab Reduces the Risk of Bone Fractures According to the results of a Phase III clinical trial, treatment with denosumab significantly reduces the risk of vertebral and hip fractures among postmenopausal... Continue Reading

Denosumab Shows Promise in Women with Postmenopausal Osteoporosis (April 11, 2008)

Denosumab Shows Promise in Women with Postmenopausal Osteoporosis A recent study conducted by the pharmaceutical company Amgen reveals that the drug denosumab significantly increased bone mineral density... Continue Reading

Bisphosphonate Use Increases Risk of Jaw Problems (July 10, 2007)

According to the results of a study published in the Journal of the National Cancer Institute, cancer patients who use intravenous bisphosphonates are more likely than nonusers to develop inflammatory... Continue Reading

MR-guided Focused Ultrasound Surgery Relieves Pain from Bone Metastases (February 2, 2007)

MR-guided Focused Ultrasound Surgery Relieves Pain from Bone Metastases According to the results of a small study published in Annals of Oncology, use of magnetic resonance-guided focused ultrasound surgery... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS